SCHEMBL3493192

SCHEMBL3493192

Cc1cc(C(=O)N2CCN(C(=O)O)C[C@H]2CNCCO)c(-c2ccccc2)n1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.38
CNR1 P21554 5/20 0.36
SMN1; SMN2 Q16637 5/20 0.36
RAB9A P51151 4/20 0.36
MAPT P10636 4/20 0.36
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 2/20 0.36
NOTUM Q6P988 1/20 0.36
LMNA P02545 4/20 0.34
TP53 P04637 3/20 0.34
HPGD P15428 2/20 0.34
HTT P42858 2/20 0.34
TSHR P16473 1/20 0.34
HCRTR1 O43613 3/20 0.33
HCRTR2 O43614 3/20 0.33
MAPK1 P28482 2/20 0.33
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13341187 0.89 KAT7 (0.39) LMNA
SCHEMBL3492063 0.88 ALDH1A1 (0.41) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL3494146 0.86 CNR2 (0.38) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL3493665 0.85 BCL2 (0.38) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL3495346 0.85 SMN1; SMN2 (0.41) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL3494849 0.84 HCRTR1 (0.46) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL8238776 0.84 HCRTR1 (0.40) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL3493841 0.83 ALDH1A1 (0.39) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL3495223 0.83 CNR2 (0.38) CNR2CNR1SMN1; SMN2RAB9AMAPT
SCHEMBL3491924 0.82 ALDH1A1 (0.41) CNR2CNR1SMN1; SMN2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
EP-1984355-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION Takeda Pharmaceutical Company Limited (JP) 2008-10-29 EP disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 CNR2 375/4885CNR1 388/4885SMN1; SMN2 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.